Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Syndax ends IPF development after phase 2 disappointment
In topline phase 2 results, Syndax’s Niktimvo did not slow worsening lung function in IPF patients compared to placebo.
Donavyn Coffey
Oct 13, 2026 11:25am
J&J pins high hopes on Icotyde amid strong debut in psoriasis
Oct 13, 2026 11:16am
How advanced AI can improve clinical trial decision-making
Brought to you by
IQVIA
BARDA hands Kaléo $96M contract for chemical threat preparedness
Oct 13, 2026 11:02am
Why AI’s Biggest Value in Pharma Is Confidence
Brought to you by
/prompt
Inside the 'first-shoring' philosophy behind ARPA-H RNA project
Oct 13, 2026 8:30am
